Clinical Trials Logo

Clinical Trial Summary

At present, prophylactic cranial irradiation (PCI) is part of standard care for patients with limited-stage small cell lung cancer (SCLC) who have achieved good response after definitive thoracic radiotherapy and chemotherapy. However, the value of PCI is being challenged in the era when MRI examination of brain has been popularized. The goal of this clinical study is to compare PCI and regular brain MRI follow-up (control arm) and regular brain MRI follow-up alone (study arm) in patients with limited-stage SCLC who have received definitive radiotherapy and chemotherapy and acheived complete remission (CR) of tumor. The main questions to answer are: 1. Whether the 2-year brain metastasis-free survival rate of the study group is not inferior to that of the control group. 2. The difference of 2-year overall survival rate between the control group and the study group. 3. Whether the patients in the study group have better overall quality of life than those in the control group. Participants will randomly receive either PCI and regular brain MRI follow-up or regular brain MRI follow-up alone.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05651802
Study type Interventional
Source Zhejiang Cancer Hospital
Contact Xiao Hu, MD, PhD
Phone +86-571-88128172
Email huxiao@zjcc.org.cn
Status Recruiting
Phase N/A
Start date January 1, 2023
Completion date June 2026

See also
  Status Clinical Trial Phase
Recruiting NCT04882033 - Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer Phase 1
Recruiting NCT04543890 - A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC Phase 2
Completed NCT03059667 - Immunotherapy as Second-line in Patient With Small Cell Lung Cancer Phase 2
Completed NCT01797159 - Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer N/A
Completed NCT03214003 - Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC N/A
Recruiting NCT04418648 - Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy Phase 2
Not yet recruiting NCT04189094 - Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC Phase 2
Recruiting NCT05945745 - Molecular Analysis and Treatment Options of SCLC
Recruiting NCT04602533 - Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) Phase 2